Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV and diabetes: scientists probe fat tissue to uncover hidden links

NCT ID NCT04451980

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at 172 people with and without HIV to understand why those with HIV have a higher risk of diabetes. Researchers examined fat tissue and immune cells to see if chronic immune activation in fat contributes to insulin resistance. The goal was to learn how HIV-related immune changes might lead to metabolic problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why people with HIV are more prone to diabetes, pointing toward new ways to prevent or manage metabolic disease.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to direct therapies, and findings may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

172 people

The number who actually took part.

Started

Aug 2017

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

HIV-positive participants are recruited from the Vanderbilt Comprehensive Care Clinic, and HIV-negative participants are recruited from Vanderbilt University Medical Center clinics

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

HIV+ Participants: Inclusion Criteria: * On antiretroviral therapy for at least 18 months * HIV-1 RNA \<400 copies/ml for the prior 12 months * CD4+ count \>350 cells/µl in the prior 12 months * HbA1c in prior 6 months within specified limits (See Figure) * Pre-menopausal by self-report or post-menopausal but not on hormone replacement therapy (HRT) Exclusion Criteria: * Known inflammatory or rheumatologic conditions * Heavy alcohol (\>11 drinks per week) or cocaine, amphetamine, or illicit (non-prescribed) opiate abuse by self-report * Current use of DPP-4 inhibitors. HIV-negative Participants: Inclusion Criteria: * A HbA1c \>6.5% or a fasting glucose \>126mg/dl, or on anti-diabetic medications for at least 6 months * Pre-menopausal by self-report or post-menopausal but not on hormone replacement therapy (HRT) Exclusion criteria: * Known inflammatory or rheumatologic conditions * Heavy alcohol (\>11 drinks per week) or cocaine, amphetamine, or illicit (non-prescribed) opiate abuse by self-report * Current use of DPP-4 inhibitors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 HIV

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.